#1 Clinical Trials Search in Europe

Belimumab

Belimumab, marketed under the brand name Benlysta, is a monoclonal antibody medication that has shown promise in treating various autoimmune conditions. This article explores the use of belimumab in clinical trials for conditions such as systemic lupus erythematosus (SLE), Sjögren’s syndrome, neuromyelitis optica spectrum disorders (NMOSD), and in transplant medicine. We’ll examine its mechanism of action, potential benefits, and safety profile across different studies.

Table of Contents

What is Belimumab?

Belimumab, also known by its brand name Benlysta, is a medication used to treat certain autoimmune diseases. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-produced molecule that’s designed to serve as a substitute antibody. Belimumab was previously known as LymphoStat-B[1].

How Does Belimumab Work?

Belimumab works by targeting a specific protein in your body called B lymphocyte stimulator (BLyS), also known as B cell activating factor (BAFF). This protein helps B cells, a type of white blood cell, to survive and produce antibodies. In some autoimmune diseases, there are too many B cells producing harmful antibodies that attack your own body. By inhibiting BLyS, belimumab reduces the number of these overactive B cells and helps to control the autoimmune response[2].

Conditions Treated with Belimumab

Belimumab is primarily used to treat the following conditions:

  • Systemic Lupus Erythematosus (SLE): This is the main condition for which belimumab is approved. SLE is a complex autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs[2].
  • Lupus Nephritis: This is a kidney inflammation caused by SLE[3].
  • Antiphospholipid Syndrome (APS): This is an autoimmune disorder characterized by blood clots, pregnancy complications, and the presence of antiphospholipid antibodies[4].

Research is ongoing to explore the potential of belimumab in treating other conditions, including:

  • Sjögren’s Syndrome: An autoimmune disease that primarily affects the glands that produce tears and saliva[1].
  • Neuromyelitis Optica Spectrum Disorders (NMOSD): A rare condition that affects the optic nerves and spinal cord[5].
  • Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD): A lung complication of systemic sclerosis, another autoimmune disease[6].

How is Belimumab Administered?

Belimumab is typically administered in one of two ways:

  1. Intravenous (IV) infusion: The medication is given directly into a vein over a period of about an hour. The usual dose is 10 mg per kilogram of body weight. Initially, it’s given every two weeks for the first three doses, then every four weeks thereafter[5].
  2. Subcutaneous injection: In some cases, belimumab can be given as an injection under the skin. This method allows for self-administration at home after proper training[3].

The duration of treatment can vary depending on the condition being treated and the individual patient’s response.

Effectiveness of Belimumab

Clinical trials have shown that belimumab can be effective in reducing disease activity in patients with SLE. The effectiveness is often measured using a tool called the SLE Responder Index (SRI), which considers improvements in disease activity scores and the absence of significant worsening in any organ system.

In studies, about 50% of patients showed a significant response to belimumab treatment after one year[2]. However, it’s important to note that not all patients respond to the treatment, and researchers are working on developing models to predict which patients are most likely to benefit from belimumab.

Potential Side Effects

Like all medications, belimumab can cause side effects. Common side effects may include:

  • Nausea
  • Diarrhea
  • Fever
  • Stuffy or runny nose
  • Sore throat
  • Cough
  • Trouble sleeping
  • Leg or arm pain
  • Depression

More serious side effects, though less common, can include severe infections, allergic reactions, and mental health issues. It’s important to discuss all potential risks with your healthcare provider[3].

Ongoing Research and Future Applications

Researchers are continually studying belimumab to understand its full potential. Some areas of ongoing research include:

  • Use in kidney transplantation: Studies are exploring whether belimumab can help prevent the body from rejecting a transplanted kidney[7].
  • Combination with other treatments: Researchers are investigating how belimumab works when combined with other medications for autoimmune diseases.
  • Long-term effects: Studies are ongoing to understand the long-term safety and effectiveness of belimumab[8].
  • Use in pregnancy: A registry has been established to collect data on pregnancies in women who have been exposed to belimumab, to better understand its effects on pregnancy outcomes[8].

As research continues, our understanding of belimumab and its potential applications in treating autoimmune diseases will likely expand, potentially offering new hope for patients with these challenging conditions.

Condition Key Findings Dosage Duration
Systemic Lupus Erythematosus (SLE) Potential to reduce disease activity, decrease autoantibodies, improve quality of life, allow steroid reduction 10 mg/kg IV Up to 52 weeks
Sjögren’s Syndrome May reduce dryness, fatigue, pain, and systemic activity 10 mg/kg IV 24-48 weeks
Neuromyelitis Optica Spectrum Disorders (NMOSD) Potential to reduce attacks and improve disability scores 10 mg/kg IV 52 weeks
Kidney Transplantation May prevent donor-specific antibody formation and improve graft survival 10 mg/kg IV 6-12 months
Graft-versus-Host Disease Prevention Potential to prevent chronic GvHD in allogeneic stem cell transplant recipients 10 mg/kg IV 6 months

FAQ

  • What is belimumab and how does it work? Belimumab is a human monoclonal antibody that targets and inhibits B-lymphocyte stimulator (BLyS), also known as B-cell activating factor (BAFF). By blocking BLyS, belimumab helps reduce the survival and activity of B cells, which play a key role in autoimmune diseases.
  • In which conditions is belimumab being studied? Belimumab is being studied in various autoimmune conditions, including systemic lupus erythematosus (SLE), Sjögren's syndrome, neuromyelitis optica spectrum disorders (NMOSD), and in transplant medicine to prevent graft rejection and desensitization.
  • What are the potential benefits of belimumab in SLE? In SLE clinical trials, belimumab has shown potential to reduce disease activity, decrease autoantibody levels, improve quality of life, and allow for reduction in corticosteroid dosage. It may also help prevent new organ damage and flares in SLE patients.
  • How is belimumab administered in clinical trials? In most clinical trials, belimumab is administered intravenously at a dose of 10 mg/kg. The typical schedule is on days 0, 14, and 28, and then every 28 days. Some trials also explore subcutaneous administration.
  • What are the main safety concerns with belimumab? The main safety concerns with belimumab include the risk of infections, hypersensitivity reactions, and depression. Clinical trials closely monitor for these and other adverse events to establish the drug's safety profile in different patient populations.

Ongoing Clinical Trials on Belimumab

  • Study of rituximab and belimumab combination compared to rituximab alone in adults with persistent or chronic immune thrombocytopenia (ITP)

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Belimumab with Rituximab and Venetoclax for Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study of Belimumab for Children with Systemic Lupus Erythematosus (SLE)

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

  • Study on Belimumab for Children with Systemic Lupus Erythematosus (SLE)

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • B-lymphocyte stimulator (BLyS): Also known as B-cell activating factor (BAFF), it is a protein that helps B cells survive and mature. Overproduction of BLyS is associated with autoimmune diseases.
  • Systemic lupus erythematosus (SLE): A chronic autoimmune disease that can affect various parts of the body, including skin, joints, kidneys, brain, and other organs.
  • Sjögren's syndrome: An autoimmune disorder characterized by dry eyes and dry mouth, often accompanied by other immune system disorders.
  • Neuromyelitis optica spectrum disorders (NMOSD): A group of rare autoimmune conditions that primarily affect the optic nerves and spinal cord, causing inflammation and damage.
  • Graft-versus-host disease (GvHD): A complication that can occur after a stem cell or bone marrow transplant, where the donor cells attack the recipient's tissues.
  • Desensitization: In transplant medicine, the process of reducing a patient's antibodies against potential donor organs to increase the chances of a successful transplant.
  • Panel reactive antibodies (PRA): A measure of the level of sensitization in transplant candidates, indicating the percentage of the donor population against which the patient has pre-formed antibodies.
  • Donor specific antibodies (DSA): Antibodies in a transplant recipient that specifically target antigens of the donor organ, increasing the risk of rejection.
  • SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment – Systemic Lupus Erythematosus Disease Activity Index, a tool used to measure disease activity in lupus patients.

References

  1. https://clinicaltrials.gov/study/NCT01160666
  2. https://clinicaltrials.gov/study/NCT04893161
  3. https://clinicaltrials.gov/study/NCT03370263
  4. https://clinicaltrials.gov/study/NCT05020782
  5. https://clinicaltrials.gov/study/NCT05154734
  6. https://clinicaltrials.gov/study/NCT06716606
  7. https://clinicaltrials.gov/study/NCT03591380
  8. https://clinicaltrials.gov/study/NCT01532310